FILING ANALYSIS · MONDAY, OCTOBER 26
Jazz Pharmaceuticals plc JAZZ — 8-K: Results of Operations and Financial Condition
negative
Jazz Pharmaceuticals expects a $755 million pre-tax charge for acquired in-process research and development expense related to the Actio Biosciences acquisition, impacting GAAP and non-GAAP EPS by approximately $11.00 for Q3 2026. This significant charge is a notable burden on the company's financials for the quarter.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →